JPH05301826A - プロリルエンドペプチダーゼ阻害剤 - Google Patents

プロリルエンドペプチダーゼ阻害剤

Info

Publication number
JPH05301826A
JPH05301826A JP3357004A JP35700491A JPH05301826A JP H05301826 A JPH05301826 A JP H05301826A JP 3357004 A JP3357004 A JP 3357004A JP 35700491 A JP35700491 A JP 35700491A JP H05301826 A JPH05301826 A JP H05301826A
Authority
JP
Japan
Prior art keywords
agent
residue
active ingredient
prolyl endopeptidase
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP3357004A
Other languages
English (en)
Japanese (ja)
Inventor
Kenichi Kimura
賢一 木村
Junji Nakamura
純二 中村
Fumiko Kano
史子 加納
Makoto Yoshihama
誠 吉浜
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Snow Brand Milk Products Co Ltd
Original Assignee
Snow Brand Milk Products Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Snow Brand Milk Products Co Ltd filed Critical Snow Brand Milk Products Co Ltd
Priority to JP3357004A priority Critical patent/JPH05301826A/ja
Priority to EP92121791A priority patent/EP0556482B1/en
Priority to DE69210797T priority patent/DE69210797T2/de
Priority to CA002086142A priority patent/CA2086142A1/en
Publication of JPH05301826A publication Critical patent/JPH05301826A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/52—Cyclic peptides containing at least one abnormal peptide link with only normal peptide links in the ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • AIDS & HIV (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
JP3357004A 1991-12-24 1991-12-24 プロリルエンドペプチダーゼ阻害剤 Pending JPH05301826A (ja)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP3357004A JPH05301826A (ja) 1991-12-24 1991-12-24 プロリルエンドペプチダーゼ阻害剤
EP92121791A EP0556482B1 (en) 1991-12-24 1992-12-22 Propyl endopeptidase inhibitor
DE69210797T DE69210797T2 (de) 1991-12-24 1992-12-22 Prolyl Endopeptidase Inhibitor
CA002086142A CA2086142A1 (en) 1991-12-24 1992-12-23 Prolyl endopeptidase inhibitor

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP3357004A JPH05301826A (ja) 1991-12-24 1991-12-24 プロリルエンドペプチダーゼ阻害剤

Publications (1)

Publication Number Publication Date
JPH05301826A true JPH05301826A (ja) 1993-11-16

Family

ID=18451883

Family Applications (1)

Application Number Title Priority Date Filing Date
JP3357004A Pending JPH05301826A (ja) 1991-12-24 1991-12-24 プロリルエンドペプチダーゼ阻害剤

Country Status (4)

Country Link
EP (1) EP0556482B1 (2)
JP (1) JPH05301826A (2)
CA (1) CA2086142A1 (2)
DE (1) DE69210797T2 (2)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4806628B2 (ja) 2003-05-05 2011-11-02 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤
EP2338490A3 (en) 2003-11-03 2012-06-06 Probiodrug AG Combinations useful for the treatment of neuronal disorders
US7304086B2 (en) 2004-02-05 2007-12-04 Probiodrug Ag Inhibitors of glutaminyl cyclase
EP2089383B1 (en) 2006-11-09 2015-09-16 Probiodrug AG 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
US9126987B2 (en) 2006-11-30 2015-09-08 Probiodrug Ag Inhibitors of glutaminyl cyclase
AU2008220785B2 (en) 2007-03-01 2013-02-21 Vivoryon Therapeutics N.V. New use of glutaminyl cyclase inhibitors
JP5667440B2 (ja) 2007-04-18 2015-02-12 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのチオ尿素誘導体
JP5934645B2 (ja) 2009-09-11 2016-06-15 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのヘテロ環式誘導体
WO2011107530A2 (en) 2010-03-03 2011-09-09 Probiodrug Ag Novel inhibitors
JP5688745B2 (ja) 2010-03-10 2015-03-25 プロビオドルグ エージー グルタミニルシクラーゼ（ｑｃ、ｅｃ２．３．２．５）の複素環阻害剤
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
EP2686313B1 (en) 2011-03-16 2016-02-03 Probiodrug AG Benzimidazole derivatives as inhibitors of glutaminyl cyclase
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa

Also Published As

Publication number Publication date
EP0556482A3 (2) 1994-01-05
DE69210797D1 (de) 1996-06-20
EP0556482A2 (en) 1993-08-25
CA2086142A1 (en) 1993-06-25
EP0556482B1 (en) 1996-05-15
DE69210797T2 (de) 1996-09-26

Similar Documents

Publication Publication Date Title
US7893020B2 (en) Bacterial efflux pump inhibitors and methods of treating bacterial infections
IL139862A (en) History of thiazolidine or pyroladine as effects of dipheptidyl peptides IV and pharmaceutical preparations containing them
WO2003017936A2 (en) Use of dppiv inhibitors as diuretic and anti-hypertensive agents
JPH05301826A (ja) プロリルエンドペプチダーゼ阻害剤
IL145568A (en) Use of dipeptidyl peptidease IV inhibitors for the preparation of pharmaceutical preparations to aid in growth
IL152022A (en) Compounds useful as protease inhibitors and pharmaceutical compositions containing the same
CN1622941A (zh) 基于谷氨酰胺酰基的dpiv抑制剂
WO2023048151A1 (ja) ウイルス増殖阻害活性を有する環状ペプチド
US20050119197A1 (en) Naadp analogues for modulating t-cell activity
JPH10101556A (ja) ファクターｄ阻害剤
US5780513A (en) Method of inhibiting the release of bioactive IL-1
US7211246B2 (en) Compositions comprising oestrone-3-0-sulphamate and trail (TNF-related apoptosis inducing ligand)
KR0124028B1 (ko) 후천성 면역 결핍증의 예방 및 치료제
CN116173015B (zh) 一种环己烯基异硫氰酸酯类化合物在制备Caspase-1抑制剂中的用途
US11554121B2 (en) Compositions and methods for inhibiting type 1 collagen production
WO1991015121A1 (en) Method for treating fungal infection
CN114699419B (zh) PLpro蛋白抑制剂在治疗或预防新型冠状病毒感染的药物中的应用
EP2605770A1 (en) Antifungal agents and uses thereof
JPWO1997037657A1 (ja) イミダゾール誘導体を含有する抗ｈｉｖ組成物
KR20050092568A (ko) 간섬유화 및 간경화 치료 효과를 갖는 아시아트산 유도체
KR101742023B1 (ko) 보르테조밉을 유효성분으로 함유하는 담석증의 예방 또는 치료용 약학적 조성물
WO2024258613A9 (en) Tetrachlorovancomycin and derivatives
KR0178575B1 (ko) 항바이러스 활성을 갖는 펩티드 모방체 화합물 및 이를 포함하는 조성물
JPH09143099A (ja) 毛様体筋緊張緩和剤
KR20230123701A (ko) 북극고래 유래 재조합 섬유아세포 성장인자 11을 유효성분으로 포함하는 항바이러스 조성물